CoChat

The Integrative Management of Treatment-Resistant Depression: A Comprehensive Review and Perspectives

Open access
Carvalho, Andre F., Berk, Michael, Hyphantis, Thomas N., McIntyre, Roger S. · 2014 · Psychotherapy and Psychosomatics

The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.

Abstract

Background: Major depressive disorder is a prevalent and disabling illness. Notwithstanding numerous advances in the pharmacological treatment of depression, approximately 70% of patients do not remit after first-line antidepressant treatment. Methods: The MEDLINE/PubMed, EMBASE and ClinicalTrials.gov electronic databases were searched from inception to October 1, 2013, for randomized controlled trials (RCT), relevant open-label trials, meta-analyses and ongoing trials of pharmacological and psychotherapeutic approaches to treatment-resistant depression (TRD). Results: Switching to a different antidepressant is a useful option following nonresponse to a first-line agent. Although widely used in clinical practice, there is limited evidence to support antidepressant combination for TRD. Notwithstanding evidence for lithium or T 3 augmentation to be successful in TRD, most studies were carried out when participants were treated with tricyclic antidepressants (TCA). Of the available strategies to augment the response to new-generation antidepressants, the use of some atypical antipsychotics is best supported by evidence. Several novel therapeutic options are currently discussed. Evidence suggests that cognitive therapy (CT) is an effective strategy for TRD. Conclusions: The success of switching to a different antidepressant following a first-line agent is supported by evidence, but there is limited evidence for effective combination strategies. Lithium and T 3 augmentation of TCA have the strongest evidence base for successful treatment of TRD. The use of augmentation of newer-generation antidepressants with atypical antipsychotics is supported by a growing evidence base. Current evidence supports CT as an effective strategy for TRD. There is a need for additional large-scale RCT of TRD. The development of new antidepressants targeting novel pathways opens a promising perspective for the management of TRD.

Overview

Integrity signals

Registry

Crossref · 10.1159/000357500

Cites

168 of 168 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 8

  1. 10.1176%2fappi.ps.60.11.1439 · doi:10.1176/appi.ps.60.11.1439 · Paper page
  2. 10.1192%2fbjp.175.1.12 · DOI · Paper page
  3. 10.1176%2fappi.ajp.163.7.1161 · doi:10.1176/appi.ajp.163.7.1161 · Paper page
  4. 10.1176%2fappi.ajp.163.9.1531 · DOI
  5. 10.1176%2fappi.ajp.163.9.1519 · DOI · Paper page
  6. 10.1159%2f000334112 · DOI
  7. 10.3109%2f10401230209147396 · doi:10.3109/10401230209147396 · Paper page
  8. 10.1176%2fappi.ajp.164.5.739 · DOI · Paper page

Cited by

See all 129

Metadata

Authors
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S.
Affiliations
  • Universidade Federal do Ceará (BR)
  • Deakin University (AU)
  • University of Ioannina (GR)
  • University Health Network (CA)
Venue
Psychotherapy and Psychosomatics
Publisher
S. Karger AG
Published
2014
Volume
83
Issue
2
Pages
70-88
ISSN
  • 0033-3190 (ISSN-L)
  • 1423-0348
OpenAlex
W1969922688
Cited by
123
References
168
Citations by year
2026: 4 · 2025: 9 · 2024: 12 · 2023: 5 · 2022: 6 · 2021: 11 · 2020: 11 · 2019: 9 · 2018: 12 · 2017: 9 · 2016: 12 · 2015: 15 · 2014: 6
FWCI
1.80
Type
journal article
Language
en
Open access
Licence
Locations
  • Psychotherapy and Psychosomatics (publishedVersion)
  • PubMed (publishedVersion)
  • Deakin Research Online (Deakin University) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
Keywords
treatment-resistant depression, major depressive disorder, antidepressant switching, antidepressant combination therapy, lithium augmentation, tricyclic antidepressants, atypical antipsychotics, cognitive therapy, newer antidepressants, psychotherapy
MeSH terms
Antidepressive Agents, Combined Modality Therapy, Humans, Cognitive Behavioral Therapy, Treatment Outcome, Antidepressive Agents, Second-Generation, Drug Substitution, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.